Major Indian Generics Go For Ensured Revenue Rather Than U.S. Patent Courts (India)

Major Indian Generics Go For Ensured Revenue Rather Than U.S. Patent Courts (India) Major Indian pharmaceutical companies tend to accept out-of-court settlements of patent suits because they realize they need a continuous revenue flow from business abroad. Ranbaxy Laboratories, Dr. Reddy's, Lupin, Ranbaxy, Sun Pharma and Wockhardt have reached settlements by suing U.S. drug makers where in the past they might have pressed their claims in court. Each of the settled cases has involved a deal to be announced later guaranteeing a continued flow of income through the U.S. maker. Industry experts say those agreements are a sign generics makers are becoming more mature. (Click here for more )